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Abstract
The purpose of this study was to characterize the direct effects of uncarboxylated
osteocalcin (ucOCN) on vascular cell biology in vitro, to assess its potential function
in pathophysiological conditions such as atherosclerosis. Human aortic endothelial
cells (HAECs) and smooth muscle cells (HASMCs) were treated with ucOCN (0.1–
50 ng/ml) and changes in phosphorylation of intracellular signaling proteins,
angiogenesis, proliferation, migration, monolayer permeability, and protein secretion
were measured. In HAECs, phosphorylated JNK and CREB were decreased with
ucOCN (p < 0.05). In HASMCs, phosphorylated p70S6K and NF‐ΚB were increased by
ucOCN (p < 0.05). Cell proliferation increased in both cell types dose dependently
which was blocked by AKT and ERK pathway inhibitors. ucOCN did not affect cell
permeability, angiogenesis, or migration. The direct activity of ucOCN on vascular
cells is recognized, particularly its proliferative effects. However, at least in
physiological settings, it does not appear that osteocalcin may directly promote
atherogenesis based on the outcomes measured.
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1 | INTRODUCTION
In recent years, the skeleton’s role as an endocrine organ has been
increasingly acknowledged and investigated, in particular its cross‐
talk with glucose and lipid metabolism (Ferron & Lacombe, 2014; Lee
et al., 2007). These links have been attributed in part to a vitamin K
dependent protein called osteocalcin (OCN), also known as bone Gla
protein or BGLAP. OCN is the most abundant noncollagenous
protein found in the bone matrix, predominantly produced by
osteoblasts (Hauschka, Lian, Cole, & Gundberg, 1989). Posttransla-
tional γ‐carboxylation of glutamic acid residues results in a
carboxylated form of OCN (cOCN) which induces a high affinity for
calcium ions. This promotes binding of cOCN to hydroxyapatite
crystal lattices present in the bone extracellular matrix. Uncarboxy-
lated osteocalcin (ucOCN) is released into the circulation, as well as
some cOCN, following a number of conditions such as decarboxyla-
tion, vitamin K deficiency, or by the acidic environment during bone
resorption (Cairns & Price, 1994; Motyl, Mccabe, & Schwartz, 2010;
Plantalech, Guillaumont, Vergnaud, Leclercq, & Delmas, 1991).
OCN has an established extra‐skeletal function through involvement
with whole body metabolism, fertility, and cognition (Ferron et al., 2010;
Hauschka et al., 1989; Lee et al., 2007; Oury et al., 2011, 2013), reviewed
elsewhere (Karsenty, 2017). A new line of enquiry into the wide‐ranging
function of OCN is its role in the vasculature, and it has been proposed as
a biomarker for cardiometabolic risk, and a potential therapeutic target
(Tacey et al., 2018). It has been reported that in older men, a lower ratio
of ucOCN/total OCN predicted myocardial infarction independently of
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Abbreviations: OCN, osteocalcin; ucOCN, uncarboxylated osteocalcin; HAEC, human aortic
endothelial cell; HASMC, human aortic smooth muscle cell.
conventional cardiovascular risk factors (Yeap et al., 2015). However,
other studies have found no association between OCN and cardiovas-
cular disease incidence (Holvik et al., 2014; Hwang et al., 2015).
Elsewhere, Yeap et al. (2012) found that total osteocalcin predicted all‐
cause mortality and cardiovascular disease‐related mortality in commu-
nity‐dwelling older men, however the relationship was U‐shaped with
men at both ends of the distribution at increased risk. Similarly,
Kanazawa, Yamaguchi, and Sugimoto (2011) performed a longitudinal
study in which a U‐shaped association between OCN and plaque score
was determined. It appears OCN may protect vascular function, which is
often mediated through an improved metabolic state involving insulin
signaling and glucose regulation (Dou et al., 2014; Jung et al., 2013; Tacey
et al., 2018). In vivo studies in rats and mice found that ucOCN may be
protective against atherosclerosis and promotes normal vascular function
(Tacey et al., 2018). Direct effects of OCN on vascular cells remains to be
confirmed through in vitro investigation. Other bone hormones such as
FGF‐23, and more recently sclerostin, have already been demonstrated
to influence vascular cells directly (Cianciolo et al., 2018; Oranger et al.,
2017).
Another particular area of interest is the relationship between
OCN and vascular calcification. This is based on the underlying
resemblance of vascular calcification to bone mineralization and
limited direct investigations with osteocalcin and the vasculature
(Evrard, Delanaye, Kamel, Cristol, & Cavalier, 2015; Idelevich, Rais, &
Monsonego‐Ornan, 2011; Millar, Patel, Anderson, England, &
O’Sullivan, 2017). Cross‐sectional epidemiological data surrounding
osteocalcin has reported conflicting associations and a meta‐analysis
of data in humans correlating OCN and markers of calcification and
atherosclerosis was inconclusive (Millar et al., 2017).
In vitro examination of OCN in human cells and exploration of its
potential role and mechanisms of actions is needed as our knowledge is
remarkably limited. To date, it has been reported that ucOCN is the
active form of OCN involved in its endocrine functions (Lacombe &
Ferron, 2015). Therefore, we undertook comprehensive in vitro experi-
ments in human aortic endothelial cells (HAECs) and human aortic
smooth muscle cells (HASMCs), assessing their response to ucOCN, with
the hypothesis that it can initiate direct intracellular signaling, and
promote angiogenesis. We aimed to report ucOCN related intracellular
pathways and cellular functions to progress understanding of its
importance under normal physiological conditions, and any indications
that ucOCN may be a promoter or suppressor of normal vascular
function. It is important to explore the effects of ucOCN on both HAECs
and HASMCs as each cell type has their distinct characteristics and role
in maintaining vascular function and homeostasis, and equally have their
own responses and involvement in vascular pathologies.
2 | MATERIALS AND METHODS
2.1 | Materials
Human uncarboxylated osteocalcin (ucOCN; amino acids 1–49,
[Glu17,21,24]) was purchased from US Biological (O8060‐09C‐USB;
Ely, UK) and AnaSpec Inc. (AS‐65307; Ely, UK). The amino acid
sequence of purchased osteocalcin was as follows: Tyr‐Leu‐Tyr‐Gln‐
Trp‐Leu‐Gly‐Ala‐Pro‐Val‐Pro‐Tyr‐Pro‐Asp‐Pro‐Leu‐Glu‐Pro‐Arg‐Arg‐
Glu‐Val‐Cys‐Glu‐Leu‐Asn‐Pro‐Asp‐Cys‐Asp‐Glu‐Leu‐Ala‐Asp‐His‐Ile‐
Gly‐Phe‐Gln‐Glu‐Ala‐Tyr‐Arg‐Arg‐Phe‐Tyr‐Gly‐Pro‐Val.
2.2 | Cell culture
HAECs and HASMCs were purchased from PromoCell (UK) and
maintained at 37°C in a humidified incubator supplemented with 5%
CO2 in commercially available endothelial cell growth media and
smooth muscle cell growth media (PromoCell), containing 1% Penicillin–
Streptomycin (Sigma‐Aldrich, UK). Cells were used between passages 3
and 5. Human ovarian cancer cell line, SKOV‐3 (American Type Culture
Collection [ATCC] HTB‐77) obtained from ATCC were cultured in
Roswell Park Memorial Institute‐1640 media (Sigma‐Aldrich) containing
10% fetal bovine serum (FBS; Sigma‐Aldrich) and 1% Penicillin–
Streptomycin. SKOV‐3 cells (passage 21) were used as a negative
control when identifying the GPRC6A receptor during western blotting.
Human osteoblasts (HOBs) were originally isolated from human femoral
head trabecular bone and have been characterized previously
(Anderson, Downes, Perry, & Caballero, 1998; Henstock, Ruktanonchai,
Canham, & Anderson, 2014; Huang, Silvio, Wang, Tanner, & Bonfield,
1997). HOBs were cultured in Dulbecco’s Modified Eagle’s Medium sup-
plemented with 10% FBS, 1% Penicillin–Streptomycin, 200 nM
L‐glutamine, and 15 µg/ml ascorbic acid (all Sigma‐Aldrich) and were
used as a positive control for measuring osteocalcin secretion from cells
by enzyme‐linked immunosorbent assay (ELISA) and for GPRC6A
receptor identification during western blotting. After experimental
treatments, cell media was collected and cells were washed with
phosphate buffered saline (PBS; pH 7.4, Gibco™, Loughborough, UK).
Radioimmunoprecipitation assay buffer (Sigma‐Aldrich) with protease
and phosphatase inhibitors (A32959; Thermo Fisher Scientific, Lough-
borough, UK) was added to lyse the cells which were then collected and
centrifuged at 14,000g for 5min at 4°C. Cell supernatants were frozen
at − 80°C or analyzed immediately, unless otherwise stated.
2.3 | Vascular permeability
HAECs were grown until confluent in 12‐well plates on 12mm diameter,
0.4 µM pore polycarbonate membrane inserts (Corning® Costar®; Sigma‐
Aldrich). Transepithelial electrical resistance (TEER) was measured using
EVOM™ voltohmmeter (World Precision Instruments, Sarasota, FL) to
evaluate paracellular permeability of cells treated with vehicle or ucOCN
(10ng/ml).
2.4 | Enzyme‐linked immunosorbent assays
Human osteocalcin DuoSet ELISA (R&D Systems; DY1419) was used
to measure total secreted osteocalcin in cell culture media.
Endothelin Pan Specific, ICAM‐1/CD54, VCAM‐1/CD106, and total
MMP‐3 DuoSet ELISAs were performed on cell culture media
according to the manufacturer’s instructions (Catalog numbers
DY1160, DY720, DY809, and DY513; R&D Systems, Abingdon, UK).
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2.5 | Proliferation assay
Cell Titre 96 AQueous One Solution Cell Proliferation Assay (Catalog
No. G3581; Promega, Southampton, UK) was performed according to
manufacturer’s instructions in HAECs and HASMCs. Cells were
seeded at approximately 5,000 cells per well in 96‐well plates and
left to adhere for at least 4 hr. Cells were then treated with control
media, or media supplemented with 0.1 ng/ml, 0.5 ng/ml, 1 ng/ml,
10 ng/ml or 50 ng/ml of ucOCN for 48 or 72 hr. The proliferation
assay was repeated with 10 ng/ml of ucOCN on confluent cells to
establish if the effects of OCN were due to an increase in cell
proliferation as opposed to an increase in cell metabolism.
The proliferation assay was repeated using 10ng/ml of ucOCN alone
or in the presence of 3 µM PI3K inhibitor (LY294002 hydrochloride;
Catalog No. 1130; Tocris Bioscience, Bristol, UK) or MAPK (MKK/MEK)
inhibitor (PD98059; Catalog No. 1213; Tocris Bioscience).
2.6 | Scratch wound/migration assay
An in vitro scratch assay with HAECs and HASMCs was performed as
described previously (Liang, Park, & Guan, 2007). Cells were seeded
in six‐well cell culture plates and left to adhere until confluent in
usual cell growth media. For the HAEC experiments, cells were then
sustained with endothelial cell basal medium (PromoCell) without
growth or supplement factors but containing 10% FBS (F9665,
Sigma‐Aldrich) to allow cell survival but limiting proliferation. For the
HASMC experiments, once confluent, cells were switched to smooth
muscle cell basal medium (PromoCell) without growth or supplement
factors but supplemented with 0.1% FBS. After 24 hr, a scratch was
marked on each well with a P200 pipette tip, washed with PBS, and
replaced with media alone, or media containing ucOCN (10 ng/ml).
Images of the scratch were captured at baseline and at various time
points to monitor cell migration. The area of the scratch wound at
baseline and at each time point was measured using the
ImageJ software.
2.7 | Angiogenesis assay
Confluent (80–100%) or sub‐confluent (50–60%) HAECs were
treated with ucOCN (10 ng/ml) or with media alone for 72 hr. The
MILLIPLEX MAP Human Angiogenesis Assay (Catalog No. HAGP1-
MAG‐12K; Merck Millipore, Hertfordshire, UK) was performed
according to the manufacturers’ instructions to detect changes in
angiopoietin‐2 (ANG‐2), vascular endothelial growth factor d
(VEGFd), hepatocyte growth factor (HGF), VEGFc, interleukin‐8
(IL‐8) and fibroblast growth factor‐2 (FGF‐2) in cell lysates.
2.8 | GPRC6A expression
HAECs, HASMCs, SKOV‐3s, and HOBs were grown until confluent
and cultured for an additional 24 hr. Cell lysates were collected and
protein samples (5 µg/lane) were resolved by electrophoresis on 10%
Mini‐protean TGX precast gels (Bio‐Rad Laboratories, Inc., Hertford-
shire, UK). The proteins were wet transferred to a nitrocellulose
membrane and incubated in blocking buffer (2% bovine serum
albumin in tris buffered saline with tween 20 [TBST]) overnight at 4°
C. The membrane was then incubated with rabbit anti‐human
GPRC6A primary antibody (Abbexa, Cambridge, UK; 1:1,000 in 3%
blocking buffer) for 2 hr at room temperature. The membrane was
then washed and incubated for 1.5 hr with alkaline phosphatase
conjugated antirabbit secondary antibody (Catalog No. A3937,
1:25,000; Sigma‐Aldrich). Immunoreactive bands were visualized by
chemiluminescence (Bio‐Rad Immun‐Star™ AP Substrate Pack
#1705012). Protein bands were visualized using the ChemiDoc™
MP Imaging system with Image Lab™ software
(Bio‐Rad Laboratories, Inc.). The membrane was then stripped for
reblotting using ReBlot Plus Mild Antibody Stripping Solution (Sigma‐
Aldrich) and then blocked with 5% marvel in TBST for 2 hr at room
temperature. The membrane was then incubated with rabbit anti‐
human beta‐actin (Abcam, Cambridge, UK; Catalog No. 8227, 1:5,000
in 3% marvel in TBST) overnight at 4°C. Finally, the membrane was
washed and incubated with secondary antibody in 3% marvel in TBST
and visualized and quantified as above.
2.9 | Cell signaling assay
HAECs and HASMCs were grown until confluent and treated with
ucOCN (10 ng/ml) or with control media for 2, 5, 10, and 30min. The
MILLIPLEX MAP 9‐plex Multi‐Pathway Magnetic Bead Signaling Kit
(48‐680MAG; Merck Millipore) was performed according to the
manufacturers’ instructions to detect changes in phosphorylated ERK/
MAP kinase 1/2 (Thr185/Tyr187), AKT (Ser473), STAT3 (Ser727), JNK
(Thr183/Tyr185), p70s6 kinase (Thr412), NF‐kB (Ser536), STAT5A/B
(Tyr694/699), CREB (Ser133), and p38 (Thr180/Tyr182) in cell lysates
using Luminex® xMAP® technology. Phosphorylated‐ and total‐mTOR
(Ser2448) were also measured in the lysate samples using the Luminex
system (48‐625MAG, Merck Millipore).
2.10 | Protein content assay
A bicinchoninic acid protein (BCA) assay was performed to quantify
the total protein content in cell lysates (Smith et al., 1985). The BCA
working reagent was prepared by mixing BCA solution with copper
(II) sulfate pentahydrate 4% solution (Sigma‐Aldrich) at a 50:1 ratio.
Protein concentrations of samples were interpolated against a bovine
serum albumin standard curve. Secreted protein concentrations,
intracellular signaling proteins, and intracellular angiogenesis mar-
kers were corrected for total protein content unless otherwise
indicated.
2.11 | Statistical analysis
For cell signaling analyses, two‐way analysis of variances (ANOVAs)
were performed using treatment (ucOCN or control) and time point
(2, 5, 10, and 30min) as factors. One‐way ANOVAs were performed
to detect differences in protein secretions and angiogenesis markers
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between treatment groups. A one‐way ANOVA was used to detect
differences in cell viability between groups. Results are presented as
mean % change to control and standard error of the mean. Multiple
comparisons were adjusted for by Dunnett’s or Sidak’s statistical
hypothesis test. All statistical analyses were performed using Prism 7
for Windows (Version 7.01, GraphPad Software Inc.). Adjusted p
values were considered significant at p < 0.05.
3 | RESULTS
3.1 | Osteocalcin directly activates intracellular
signaling responses in HAECs and HASMCs
It was found that secreted osteocalcin was not detectable in untreated
HAECs or HASMCs following 72hr of confluence (Figure S1A).
In HAECs, treatment with ucOCN reduced phosphorylation levels
of CREB at 30min (p < 0.05; Figure 1a). Phosphorylated JNK was
decreased at 10min with ucOCN (p < 0.05; Figure 1b). ucOCN
appeared to decrease p38 phosphorylation and increase ERK
phosphorylation but this did not reach significance (Figure 1c,d).
There were no significant differences in phosphorylation of NF‐kB,
AKT, p70s6k, STAT3, STAT5, or mTOR with ucOCN treatment
compared with control (Figure 1e–j).
In HASMCs, 10‐min treatment with ucOCN increased NF‐kB
phosphorylation levels compared to control (p < 0.05; Figure 2e). In
contrast, after 30min, ucOCN decreased NF‐kB phosphorylation
compared to control (p < 0.05; Figure 2e). Phosphorylated p70s6k
concentrations were increased at 10min following ucOCN treatment
(p < 0.05; Figure 2g). Phosphorylated STAT5 was decreased after
30min (p < 0.05; Figure 2i). Phosphorylated AKT levels appeared
increased with ucOCN after 10min but this did not reach significance
(Figure 2f). No significant differences were observed for levels of
phosphorylated CREB, JNK, ERK, p38, STAT3, or mTOR with ucOCN
treatment compared to control (Figure 2a–d,h,j).
3.2 | Osteocalcin increases cell proliferation but
not migration or angiogenesis markers in HAECs
As our results indicated a direct effect of ucOCN in vascular cells, we
went on to examine whether OCN influenced stages of angiogenesis of
endothelial cells (matrix degradation, proliferation, and migration).
There were no significant differences in cell migration/wound closure
rates between treatments (control or ucOCN; Figure 3a,b). The
potential influence on matrix degradation was assessed by matrix
metalloproteinase‐3 (MMP‐3) production after 24–72 hr. MMP‐3
secretion was not affected by ucOCN compared to control (Figure
3e). However, after 72 hr of treatment ucOCN increased proliferation
(0.5, 1.0, and 10.0 ng/ml; p < 0.05; Figure 3c). The effect of ucOCN on
HAEC proliferation was no longer observed when cells were cotreated
with AKT or ERK inhibitors (Figure 3d). When a similar experiment
was conducted in already confluent cells treated with ucOCN, there
were no significant differences between groups, suggesting OCN is not
affecting cellular metabolism (Figure S1b,c). In addition, a panel of
angiogenesis markers were measured after treatment with ucOCN in
confluent and subconfluent cells. After 72 hr of incubation, there were
no differences in angiogenic regulators (ANG‐2, HGF, FGF‐2, VEGFc,
IL‐8, and VEGFd) between treatment groups in confluent experimental
conditions nor in still growing, subconfluence cells (Figure 4a–f).
3.3 | Osteocalcin increases cell proliferation in
HASMCs but not migration
Our results showed that ucOCN did not affect the rate of wound closure
(Figure 5a,b). Supporting this, we found ucOCN did not affect production
F IGURE 1 The effects of osteocalcin on human aortic endothelial cell signaling. (a–i) Luminex® xMAP® technology was used to detect
changes in phosphorylated CREB (pS133), JNK (pT183/pY185), NFkB (pS536), p38 (pT180/pY182), ERK (pT185/pY187), Akt (pS473), p70 S6K
(pT412), STAT3 (pS727), and STAT5A/B (pY694/699) (Milliplex™, 48‐680MAG, Merck Millipore) in cell lysates when treated with ucOCN
(10 ng/ml) for 2, 5, 10, and 30min (n = 10 for control and n = 20 for ucOCN from three experimental repeats, normalized to total protein).
(j) Changes in phosphorylated mTOR in cell lysates were also detected using the Luminex system (n = 8 for control and n = 16 for ucOCN from
three experimental repeats, normalized to total mTOR; Milliplex™, 48‐625MAG, Merck Millipore). Data were analyzed by two‐way ANOVA.
Multiple comparisons were adjusted for by Sidak’s statistical hypothesis test. Data are given as means with error bars representing SEM.
*Denotes a significant difference compared to control (p < 0.05). ANOVA: analysis of variance; SEM: standard error of mean; ucOCN:
uncarboxylated osteocalcin
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F IGURE 2 The effects of osteocalcin on human aortic smooth muscle cell signaling. (a–i) Luminex® xMAP® technology was used to detect
changes in phosphorylated CREB (pS133), JNK (pT183/pY185), NFkB (pS536), p38 (pT180/pY182), ERK (pT185/pY187), Akt (pS473), p70 S6K
(pT412), STAT3 (pS727), and STAT5A/B (pY694/699) (Milliplex™, 48‐680MAG, Merck Millipore) in cell lysates when treated with ucOCN
(10 ng/ml) for 2, 5, 10, and 30min (n = 10 for control and n = 20 for ucOCN, from three experimental repeats, normalized to total protein).
(j) Changes in phosphorylated mTOR in cell lysates were also detected using the Luminex system (n = 6 for control and n = 12 for ucOCN from
three experimental repeats, normalized to total mTOR; Milliplex™, 48‐625MAG, Merck Millipore). Data were analyzed by two‐way ANOVA.
Multiple comparisons were adjusted for by Sidak’s statistical hypothesis test. Data are given as means with error bars representing SEM.
*Denotes a significant difference compared to control (p < 0.05). ANOVA: analysis of variance; SEM: standard error of mean; ucOCN:
uncarboxylated osteocalcin
F IGURE 3 The effects of osteocalcin on human aortic endothelial cell (HAEC) migration and proliferation. (a) Representative images from a
scratch wound assay performed in HAECs in which the scratch area was monitored for up to 12 hr. (b) Rate of migration/closure of scratch of
HAECs treated with either vehicle or ucOCN (10 ng/ml; n = 12 for control and n = 24 for ucOCN, from three experimental repeats). (c) ucOCN
concentration‐effect (0.1–50.0 ng/ml) on cell proliferation as measured by MTS assay after 72 hr (n = 16 from three experimental repeats).
Control media and osteocalcin prepared media was replaced after 48 hr. (d) Cell proliferation was further assessed using PI3K inhibitor
(LY294002 hydrochloride 3 µM) and MAPK (MKK/MEK) inhibitor (PD98059 3 µM) (three repeats, total at least n = 9). (e) MMP‐3 secretion over
24–72 hr by HAECs treated with vehicle or ucOCN (10 ng/ml; n = 9 for control and n = 18 for ucOCN, from three experimental repeats). Data
are given as means with error bars representing SEM. Data were analyzed by one‐way ANOVA and multiple testing corrected for by Dunnet’s
statistical test. *Denotes a significant difference compared to control (*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001). #Denotes significant
difference compared to ucOCN. ucOCN, uncarboxylated osteocalcin; MMP‐3, matrix metalloproteinase‐3; MTS: Cell Titre 96 AQueous One
Solution Cell Proliferation Assay
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of MMP‐3 after 24–72hr incubation (Figure 5e). ucOCN (0.5, 1.0, and
10.0 ng/ml) significantly increased cell proliferation after 48 hr compared
to control (Figure 5c). This effect was blocked when cells were cotreated
with either AKT or ERK pathway inhibitors (Figure 5d).
3.4 | Osteocalcin does not affect endothelial cell
permeability or adhesion makers
Acute treatment with ucOCN did not affect endothelial cell
permeability, as measured using TEER over 7.5 hr (Figure 6a).
Adhesion molecules VCAM‐1 and ICAM‐1 were measured in HAECs
and HASMCs respectively. ucOCN did not affect their secretion over
time (Figure 6b,d). In addition, ucOCN did not affect production of
endothelin, a vasoconstrictor, in HAECs (Figure 6c).
3.5 | Posited osteocalcin receptor, GPRC6A, is
present in HAECs and HASMCs
The proposed osteocalcin receptor, GPRC6A, was detected in HAECs,
HASMCs, and HOBs (positive control), and not in SKOVS (negative
control) via western blotting (Figure 7).
4 | DISCUSSION
The aim of this study was to examine the direct vascular effects of
physiologically relevant concentrations of osteocalcin (Binkley, Krueger,
Engelke, Foley, & Suttie, 2000; Hannemann et al., 2013; Luukinen et al.,
2000). ucOCN activated acute cell signaling cascades in HAECs and
HASMCs, suggesting there is a molecular target for OCN on these cells.
In both cell types, ucOCN increased proliferation through ERK and AKT
signaling pathways. OCN does not appear to play a role in migration,
endothelial cell angiogenesis or permeability.
In humans, the BGLAP (bone gamma‐carboxyglutamate protein)
gene for encoding OCN is ubiquitously expressed in brain, colon,
appendix, and many other tissues (NCBI, ). However, data on protein
expression is less widely available. OCN has been implicated in
vascular calcification plaques (Bini, Mann, Kudryk, & Schoen, 1999;
Dweck et al., 2014; Foresta et al., 2013; O’Neill & Adams, 2014;
Rajamannan et al., 2005), and differentiated osteoblast‐like HASMCs
are known to produce OCN during vascular calcification and
mineralization (Dhore et al., 2001). Our results found that OCN
expression was not detectable in HASMC or HAEC supernatants or
intracellularly in normal physiological conditions, suggesting that
OCN production from HASMCs is restricted to a pathophysiological
setting exclusive to transdifferentiated HASMCs.
ucOCN is found within the circulation although there are no
standardized reference values. Total OCN concentrations have been
reported by Hannemann et al. (2013) by age and gender. However,
reported serum ucOCN concentrations largely varied between <1
and >30ng/ml (Binkley et al., 2000; Iki et al., 2012; Plantalech et al.,
1991; Sowers et al., 1999). We therefore used 10 ng/ml which has also
been used in previous in vitro studies (Dou et al., 2014; Jung et al., 2013).
We aimed to examine whether exogenously added fully un-
carboxylated OCN can directly affect intracellular signaling in HAECs
and HASMCs. We found that ucOCN significantly altered
F IGURE 4 The effects of osteocalcin on
markers of angiogenesis in human aortic
endothelial cells. (a–f) Luminex® xMAP®
technology (Milliplex™, 48‐680MAG,
Merck Millipore) was used to detect
changes in markers of angiogenesis
(angiopoietin‐2, VEGFd, HGF, VEGFc, IL‐8,
and FGF‐2) in cell lysates following
treatment with ucOCN (10 ng/ml, 72 hr) on
subconfluent and confluent cells (n = 9 for
control and n = 18 for ucOCN, from three
experimental repeats). In the confluent
cells, control media and osteocalcin
containing media was replaced every 24 hr.
In subconfluent cells, media was not
replaced during the 72 hr. ucOCN:
uncarboxylated osteocalcin; ANG‐2:
angiopoietin‐2; VEGFd: vascular
endothelial growth factor d; HGF:
hepatocyte growth factor; VEGFc: vascular
endothelial growth factor c; IL‐8:
interleukin‐8; FGF‐2: fibroblast growth
factor‐2
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phosphorylation levels of numerous signaling proteins including
CREB and JNK in HAECs, and NF‐kB and p70s6K in HASMCs. Jung
et al. (2013) has previously reported an increase in AKT phosphor-
ylation and eNOS and nitric oxide (NO) production in a PI3‐kinase
dependent manner in HAECs when treated with ucOCN for 1 hr
(0.3–30 ng/ml; Jung et al., 2013). Overall, these results evidence that
there is a direct and rapid intracellular response to osteocalcin in
HAECs and HASMCs, likely to be receptor‐mediated.
The G protein‐coupled receptor, class C, group 6, subtype A
(GPRC6A) is a recently “de‐orphaned” receptor co‐activated by cations,
for example, calcium, and basic L‐α‐amino acids (Clemmensen, Smajilovic,
Wellendorph, & Brauner‐Osborne, 2014; Wellendorph & Brauner‐
Osborne, 2004). Osteocalcin and testosterone have been proposed to
also be agonists to this receptor, which is present in rat arteries (Harno
et al., 2008; Oury et al., 2011; Pi, Parrill, & Quarles, 2010; Pi, Wu, &
Quarles, 2011). However, others have failed to reproduce and confirm
these propositions with osteocalcin (Jacobsen et al., 2013; Rueda et al.,
2016). In this paper, we present evidence for the existence of the
GPRC6A receptor in both HAECs and HASMCs. Delineation of the
specificity and functional response of GPRC6A to OCN in the human
vasculature remains to be shown, however there is a lack of a selective
receptor antagonist. Attempts at siRNA knock‐down of the receptor may
prove fruitful but we did not achieve successful knockdown in our
attempts (data not shown). Another receptor, GPR158 has also been
recently shown to mediate OCN’s effect of cognitive function in mice
(Khrimian et al., 2017) which also merits investigation in vascular cells.
Furthermore, we examined whether ucOCN affected stages of
angiogenesis such as matrix degradation, migration, and proliferation.
ucOCN did not affect MMP‐3 production or wound healing in vitro.
However, ucOCN was shown to increase proliferation in both HAECs
and HASMCs, in a dose‐dependent, bell‐shaped manner, which adds
to previously reported antiapoptotic effects of osteocalcin in HAECs
(Jung et al., 2013). ucOCN has been previously reported as
protective against free fatty acid induced apoptosis and low
concentrations of ucOCN (0.3 ng/ml) has been shown to increase
markers of pancreatic β‐cell proliferation (Ferron, Hinoi, Karsenty, &
Ducy, 2008). We revealed that osteocalcin is working through both
AKT and ERK converging pathways to translate the increase in
proliferation (Mendoza, Er, & Blenis, 2011). We chose these path-
ways to examine as it has been previously demonstrated by our
group (unpublished data) that OCN increases AKT and ERK
phosphorylation at longer time points (e.g. 24 hr) in HASMCs, and
another study has also demonstrated increases in AKT phosphoryla-
tion in HAECs with OCN (Jung et al., 2013).
F IGURE 5 The effects of osteocalcin on human aortic smooth muscle cell (HASMC) migration and proliferation. (a) Representative images
from a scratch wound assay performed in HASMCs in which the scratch area was monitored for up to 48 hr. (b) Rate of migration/closure of
scratch of HASMCs treated with either vehicle or ucOCN (10 ng/ml; n = 23 from four experimental repeats). (c) ucOCN concentration‐
dependent effect (0.1–50.0 ng/ml) on cell proliferation as measured by MTS assay after 48 hr (n = 12 from three experimental repeats). (d) Cell
proliferation was further assessed using PI3K inhibitor (LY294002 hydrochloride) and MAPK (MKK/MEK) inhibitor (PD98059) (three
experimental repeats, total at least n = 9). (e) MMP‐3 secretion over 24–72 hr by HAECs treated with vehicle or ucOCN (10 ng/ml; n = 12 for
control and n = 24 for ucOCN, from three experimental repeats). One‐way ANOVAs were used to analyze proliferation data and multiple testing
corrected for by Dunnett’s statistical test. Data are given as means with error bars representing SEM. *Denotes a significant difference
compared to control (*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001). #Denotes significant difference compared to ucOCN. ANOVA: analysis
of variance; SEM: standard error of mean; MMP‐3, matrix metalloproteinase‐3; MTS: Cell Titre 96 AQueous One Solution Cell Proliferation
Assay; ucOCN, uncarboxylated osteocalcin
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It has been previously shown in an in vivo chick embryo angiogenesis
model that osteocalcin promotes angiogenesis (Cantatore, Crivellato,
Nico, & Ribatti, 2005). Interestingly, ucOCN did not affect any of the
measured angiogenesis regulators. The discrepancy may be due to the
use of human cells in our study, within which the effects of OCN may be
less pronounced or nonexistent. Our results may indicate that osteocalcin
is working to promote proliferation, at least in HAECs, via mechanisms
independent of key angiogenic markers. ucOCN also does not appear to
acutely increase mTOR phosphorylation, which is a central regulator of
cell growth required for angiogenesis and proliferation. These novel
findings suggest that OCN may affect vascular cells in a limited range of
function, pertaining to proliferation in normal physiological conditions.
OCN did not affect cell permeability. This is a pivotal finding as
cell layer integrity is essential to vascular function and degradation is
a key, early event in atherogenesis, plaque formation and cell barrier
infiltration. We also demonstrated that ucOCN does not influence
two key endothelial cell proteins; endothelin, a potent vasoconstric-
tor, and VCAM‐1. VCAM‐1 expression is increased during inflamma-
tion and by cytokines, and as such we have found no evidence to
suggest that osteocalcin is involved in the adhesion of monocytes and
other cells to the endothelium, nor acts as a promotor of
vasoconstriction. In the aortic smooth muscle cells, ICAM‐1, which
functions as a leukocyte recruiter and may be thought of as pro‐
inflammatory, was not affected by osteocalcin.
There are several circulating forms of OCN that can be found in
the circulation including carboxylated OCN to varying degrees (0–2
carboxylated glutamic acid residues), and N‐terminal fragments
(Garnero, Grimaux, Seguin, & Delmas, 1994). It is unknown the
extent to which structural differences may play in their biological
functions (Li, Zhang, Yang, Li, & Dai, 2016). It is a limitation of the
current work that not all present circulating forms could be
examined. We recommend ex vivo and in vivo studies be performed
to fully understand the effects of OCN on the vasculature.
The in vitro investigations conducted here lay a foundation for
further research into the vascular effects of osteocalcin. ucOCN
initiates direct responses in human aortic endothelial and smooth
muscle cells and is proproliferative. However, the lack of effect of
OCN on a range of endpoints such as VCAM‐1, MMP‐3, endothelin‐1,
F IGURE 6 The effects of osteocalcin on vascular cell permeability, endothelin and adhesion markers. (a) Transepithelial electrical
resistance measurement was used to evaluate the paracellular permeability of confluent human aortic endothelial cell monolayers treated with
or without ucOCN and cOCN (n = 10 for control and n = 20 for ucOCN, from five experimental repeats). ucOCN (10 ng/ml) did not affect
secretion of VCAM‐1 (b) or endothelin‐1 (c) after 24, 48 and 72 hr (n = 14 for control and n = 28 for ucOCN, from three experimental repeats)
from confluent human aortic endothelial cells. (d) Secretion of ICAM‐1 did not differ over 24–72 hr between vehicle or ucOCN (both 10 ng/ml)
in confluent human aortic smooth muscle cells (n = 12 for control and n = 24 for ucOCN, from three experimental repeats). Data are given as
means with error bars representing SEM. ICAM‐1: intracellular adhesion molecule‐1; SEM: standard error of mean; ucOCN: uncarboxylated
osteocalcin; VCAM‐1: vascular cell adhesion molecule‐2
F IGURE 7 Posited osteocalcin receptor, GPRC6A, is present in
human aortic endothelial (HAEC) and smooth muscle cells (HASMC).
Western blot data showing lack of presence of GPRC6A in ovarian
carcinoma cells (SKOV‐3; negative control), and presence in
HASMCs, HAECs, and human osteoblasts (HOBS; positive control).
Data are given as means with error bars representing SEM
(n = 2). SEM: standard error of mean
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and cell permeability, do not suggest a direct involvement of OCN in
atherogenesis or blood vessel disease at least in physiological
settings. Further investigations within pathological settings and
examination of the biological activity of other various fragments of
osteocalcin should be undertaken.
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